- In pediatric and adolescent patients receiving moderate/highly emetogenic chemotherapy (MEC/HEC) for Hodgkin lymphoma (HL), the addition of aprepitant (AP) to dexamethasone+ondansetron significantly reduced chemotherapy-induced vomiting and was well tolerated.
- AP was not associated with a significant reduction in nausea.
Why this matters
- Chemotherapy-induced nausea and vomiting (CINV) can negatively affect QoL and treatment adherence.
- Study to compare AP+dexamethasone+ondansetron (n=32) vs standard antiemetic therapy comprising dexamethasone+ondansetron (n=23) in 55 pediatric and adolescent patients receiving MEC/HEC for HL.
- Patients provided global evaluation of nausea intensity using the Baxter Retching Faces (BARF) scale of 1-10.
- Funding: None disclosed.
- 6.66% rate of vomiting occurrence with AP vs 56.52% without (P=.0001).
- 63.33% rate of nausea occurrence with AP vs 65.21% without (P=.8873).
- Neutropenia and hypertransaminasemia were the most common adverse events and were related to chemotherapy rather than to AP; no significant difference in their incidence by treatment group (P=.37 for neutropenia; P=.52 for hypertransaminasemia).
- Higher incidence of emesis was associated with higher number of chemotherapy cycles, suggesting a correlation with chemotherapy accumulation.
- Data for nausea and vomiting were self-reported via questionnaire.